Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Only 15-20% of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients derive long-term benefit from nivolumab or pembrolizumab. We developed a ctDNA tumor-agnostic assay aimed at the early prediction of single agent PD-1 inhibitor efficacy in R/M SCCHN. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 7, 2023 Category: Cancer & Oncology Authors: Natasha Honor é, Athenaïs van der Elst, Anne Dietz, Cédric van Marcke, Raphael Helaers, Antonella Mendola, Hajar Dahou, Etienne Marbaix, Renaud Poncin, Emanuel Seront, Sandra Schmitz, Nisha Limaye, Rachel Galot, Jean-Pascal Machiels Tags: Original Research Source Type: research
Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression
This study aims to provide a comprehensive clinico-pathological and molecular profile of HER2 Low BC including response to therapy and patient outcome in the adjuvant and neoadjuvant settings. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 7, 2023 Category: Cancer & Oncology Authors: N.M. Atallah, M. Haque, C. Quinn, M.S. Toss, S. Makhlouf, A. Ibrahim, Andrew R Green, M. Alsaleem, C.S. Rutland, C. Allegrucci, N.P. Mongan, E. Rakha Tags: Original Research Source Type: research
Clinical utility of Plasma ctDNA sequencing in metastatic urothelial cancer
Genomic stratification may help improve the management of patients with metastatic urothelial cancer (mUC), given the recent identification of targetable alterations. However, the collection of tissue samples remains challenging. Here, we assessed the clinical utility of plasma circulating tumor DNA (ctDNA) sequencing in these patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 6, 2023 Category: Cancer & Oncology Authors: C. Helal, C. Pobel, A. Bayle, D. Vasseur, C. Nicotra, F. Blanc-Durand, N. Naoun, A. Bernard-Tessier, A. Patrikidou, E. Colomba, R. Flippot, A. Fuerea, N. Auger, M. Ngo Camus, B. Besse, L. Lacroix, E. Rouleau, S. Ponce, A. Italiano, Y. Loriot Source Type: research
Immune checkpoint inhibitors-associated myocarditis without cardiovascular symptoms
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 2, 2023 Category: Cancer & Oncology Authors: Jonathan Abitbol, Anais Vallet, Emilie Routier, Sondes Smaali, Caroline Robert Tags: Letter to the Editor Source Type: research
Immune effector cell-associated acute stroke: a novel entity?
Chimeric antigen receptor (CAR) T-cells may induce neurologic toxicity referred to as immune effector cell-associated neurotoxicity syndrome (ICANS). Its pathophysiology, although not fully understood, seems to be due to the permeabilization of the blood brain barrier [1,2], which induces a local capillary leak and an increase of cytokine concentration in the brain leading to cerebral edema [3]. Here, we report four cases of ischemic strokes that occurred after CAR T-cell infusion. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 29, 2023 Category: Cancer & Oncology Authors: Matteo Mauget, Sophie Lemercier, Roch Houot, Guillaume Manson Tags: Letter to the Editor Source Type: research
Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer
To the Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 28, 2023 Category: Cancer & Oncology Authors: Santiago Aix Ponce, Sophie Cousin, Paul Dubos, Laila Belcaid, Arnaud Bayle, Antoine Italiano Tags: Letter to the Editor Source Type: research
Corrigendum to “Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database” Eur J Cancer. 2023 Jan;178:162–170
The authors regret that Fig. 2B was accidently excluded from the final manuscript. This has now been corrected. The authors would like to apologise for any inconvenience caused. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 28, 2023 Category: Cancer & Oncology Authors: Ofer Margalit, William S. Harmsen, Einat Shacham-Shmueli, Molly M. Voss, Ben Boursi, Anna D. Wagner, Romain Cohen, Curtis L. Olswold, Leonard B. Saltz, Daniel A. Goldstein, Herbert Hurwitz, Niall C. Tebbutt, Fairooz F. Kabbinavar, Richard A. Adams, Benois Tags: Corrigendum Source Type: research
Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162 –170
The authors regret that Fig. 2B was accidently excluded from the final manuscript. This has now been corrected. The authors would like to apologise for any inconvenience caused. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 28, 2023 Category: Cancer & Oncology Authors: Ofer Margalit, William S. Harmsen, Einat Shacham-Shmueli, Molly M. Voss, Ben Boursi, Anna D. Wagner, Romain Cohen, Curtis L. Olswold, Leonard B. Saltz, Daniel A. Goldstein, Herbert Hurwitz, Niall C. Tebbutt, Fairooz F. Kabbinavar, Richard A. Adams, Benois Tags: Corrigendum Source Type: research
The Role of Her-2 in Penile Squamous Cell Carcinoma Progression and Cisplatin Chemoresistance and Potential for Antibody-Drug Conjugate-Based Therapy
Cisplatin-based chemotherapy has been the first choice for advanced penile squamous cell carcinoma (PSCC) in the last decade, bu its utility is limited by the low response rate, systemic toxicity and chemoresistance, which contribute to a poor prognosis. There is no standard second-line therapy for advanced PSCC. Her-2-targeted antibody –drug conjugates (ADCs) are novel low-toxicity agents which have greatly improved clinical outcomes for several advanced cancers. We aimed to explore the expression pattern, clinical significance, and oncogenic roles of Her-2 and the therapeutic potential of Her-2-targeted ADCs in PSCC. (...
Source: European Journal of Cancer - September 28, 2023 Category: Cancer & Oncology Authors: Xingliang Tan, Yanjun Wang, Zhiming Wu, Qianghua Zhou, Yi Tang, Zhicheng Liu, Gangjun Yuan, Sihao Luo, Yuantao Zou, Shengjie Guo, Na Han, Kai Yao Tags: Original Research Source Type: research
New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables!
The International Federation of Gynecology and Obstetrics (FIGO) presented recently, 14 years after FIGO 2009, its new 2023 staging system for endometrial cancers (Table 1) [1]. The changes incorporate not only a number of new prognostic pathological variables but also new molecular classifiers. FIGO should be applauded for incorporating these new variables in a consistent and well documented way and for introducing a molecular classification based on whole genome sequencing findings in endometrial carcinoma of The Cancer Genome Atlas (TCGA) [2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Ignace Vergote, Xavier Matias-Guiu Tags: Editorial Source Type: research
European trends in ovarian cancer mortality, 1990 –2020 and predictions to 2025
Over the last decades, ovarian cancer mortality in Europe has been decreasing, but disparities in trends were observed. In this paper, we analysed ovarian cancer mortality trends in Europe over the period 1990 –2020 and predicted the number of deaths and rates by 2025. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 25, 2023 Category: Cancer & Oncology Authors: Cezary Wojty ła, Paola Bertuccio, Wojciech Giermaziak, Claudia Santucci, Anna Odone, Michał Ciebiera, Eva Negri, Andrzej Wojtyła, Carlo La Vecchia Tags: Original Research Source Type: research
European trends in ovarian cancer mortality, 1990-2020 and predictions to 2025
Over the last decades ovarian cancer mortality in Europe has been decreasing, but disparities in trends were observed. In this paper, we analyzed ovarian cancer mortality trends in Europe over the period 1990-2020 and predicted the number of deaths and rates to 2025. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 25, 2023 Category: Cancer & Oncology Authors: Cezary Wojty ła, Paola Bertuccio, Wojciech Giermaziak, Claudia Santucci, Anna Odone, Michał Ciebiera, Eva Negri, Andrzej Wojtyła, Carlo La Vecchia Source Type: research
Myoepithelial carcinoma of soft tissues and bone
Myoepithelial carcinoma occurs mainly in salivary glands but rarely can also occur in soft tissues or bone. In this paper we evaluated the role of surgical margins, radiotherapy, and chemotherapy in myoepithelial carcinoma of soft tissues and bone (MC-SB) treated at our Institute. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 25, 2023 Category: Cancer & Oncology Authors: Hisaki Aiba, Costantino Errani, Giovanni Ciani, Marco Gambarotti, Alberto Righi, Margherita Maioli, Paolo Spinnato, Giorgio Frega, Toni Ibrahim, Alessandra Longhi Source Type: research
Does perioperative immunotherapy reduce the risk of second primary cancers?
The landscape of cancer treatment has evolved significantly over the years, with neoadjuvant and adjuvant use of immune checkpoint blockers (ICBs) emerging as critical component of cancer care. Neoadjuvant immunotherapy aims to reduce the risk of disease relapse through a shorter treatment course, improving treatment adherence and healthcare resource utilization. It can lead to tumor downsizing for less invasive surgery or help determine the best local treatment approach based on tumor response [1, 2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 25, 2023 Category: Cancer & Oncology Authors: Marco Tagliamento, Jordi Remon, David Planchard, Benjamin Besse Source Type: research
Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 23, 2023 Category: Cancer & Oncology Authors: Martina Ubaldi, Maria Chiara Sergi, Flavio Falcinelli, Mario Mandal à Tags: Letter to the Editor Source Type: research
